Get the Stockscreener App
1.76
2.33%
0.04
After Hours:
1.76
Bluejay Diagnostics Inc stock is traded at $1.76, with a volume of 15,877.
It is up +2.33% in the last 24 hours and down -1.12% over the past month.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
See More
Previous Close:
$1.72
Open:
$1.72
24h Volume:
15,877
Relative Volume:
0.12
Market Cap:
$1.82M
Revenue:
-
Net Income/Loss:
$-6.85M
P/E Ratio:
-0.1141
EPS:
-15.4314
Net Cash Flow:
$-6.23M
1W Performance:
-6.63%
1M Performance:
-1.12%
6M Performance:
-74.57%
1Y Performance:
-74.86%
1-Day Range:
$1.72
$1.76
1-Week Range:
$1.6901
$1.935
52-Week Range:
$1.649
$16.68
Bluejay Diagnostics Inc Stock (BJDX) Company Profile
Name
Bluejay Diagnostics Inc
Sector
Industry
Phone
(978) 631-0152
Address
360 MASSACHUSETTS AVENUE, SUITE 203, ACTON
Compare BJDX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BJDX
Bluejay Diagnostics Inc
|
1.76 | 1.78M | 0 | -6.85M | -6.23M | -15.43 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bluejay Diagnostics Inc Stock (BJDX) Latest News
Bluejay Diagnostics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Bluejay fixes sepsis test production issues, keeps 510(k) plan in view - Stock Titan
Bluejay Diagnostics (NASDAQ: BJDX) Q1 loss highlights urgent $20M funding need - Stock Titan
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update - The Manila Times
Bluejay Diagnostics (NASDAQ: BJDX) details Q1 2026 cash and sepsis test progress - Stock Titan
BJDX Stock Price, Quote & Chart | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Bluejay Diagnostics (NASDAQ: BJDX) seeks reverse split and major stock plan expansion - Stock Titan
BJDX Technical Analysis | Trend, Signals & Chart Patterns | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Bluejay Diag (BJDX) Innovation Pipeline | Q4 2023: Profit DisappointsMargin Compression - newser.com
BJDX Ownership | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Why Is Bluejay Diagnostics, Inc. (BJDX) Stock Down Today? - Meyka
Board seeks flexible reverse split, plan increase at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan
Is Bluejay Diag (BJDX) stock risky (Slight Dip) 2026-04-20Social Flow Trades - Cổng thông tin điện tử Tỉnh Sơn La
bjdx stock: Bluejay Diagnostics Overview - Bitget
Aug Summary: How is Bluejay Diagnostics Inc managing supply chain issues2026 Technical Patterns & Growth Focused Entry Reports - baoquankhu1.vn
Macro Review: Is Bluejay Diagnostics Inc gaining market share2026 Trading Recap & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Bluejay Diagnostics Nears Completion of SYMON-II Clinical Trial with 624 Patient Enrollments for Symphony IL-6 Sepsis Test - Minichart
Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial - TipRanks
SYMON-II sepsis trial nears full enrollment at Bluejay (NASDAQ: BJDX) - Stock Titan
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial - Bitget
Bluejay Diagnostics, Inc. Announces Completion Of 624 Patient Enrollments In Symon-Ii Pivotal Clinical Trial - TradingView — Track All Markets
Bluejay Diagnostics Achieves Milestone with 624 Patients Enrolled in Pivotal SYMON-II Trial for IL-6 Testing in Sepsis Management - Quiver Quantitative
BJDX Technical Analysis & Stock Price Forecast - Intellectia AI
Are insiders buying or selling Bluejay Diag (BJDX) Stock | Price at $1.95, Up 3.17%Pro Trader Recommendations - UBND thành phố Hải Phòng
Volume Recap: Why is Bluejay Diagnostics Inc stock going down2026 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
Analyst Upgrade: How is Bluejay Diagnostics Inc managing supply chain issuesNew Guidance & Real-Time Buy Zone Alerts - baoquankhu1.vn
BJDX SEC FilingsBluejay Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BJDX PE Ratio & Valuation, Is BJDX Overvalued - Intellectia AI
Bluejay Diagnostics, Inc. Enters Securities Purchase Agreement for $25,000 Private Placement of Common Stock - Minichart
Bluejay Diagnostics Announces Insider-Funded Private Stock Placement - TipRanks
Bluejay Diagnostics completes $125,000 private placement with board members - Investing.com
Bluejay Diagnostics Raises $125,000 in Insider Private Placement at $2.00 Per Share - tradingview.com
Bluejay Diagnostics (NASDAQ: BJDX) insiders purchase $125K in private stock deal - stocktitan.net
Fed Meeting: Is Bluejay Diagnostics Inc gaining market shareEntry Point & Weekly Return Optimization Alerts - baoquankhu1.vn
Bluejay Diagnostics, Inc. announced that it has received $0.125 million in funding - marketscreener.com
Bluejay Diagnostics Evaluates Potential Acquisition Opportunity While Prioritizing Core Critical Care Platform Initiatives - Minichart
Bluejay Diagnostics sends response letter to NorthStrive Fund II LP By Investing.com - Investing.com India
Bluejay Diagnostics sends response letter to NorthStrive Fund II LP - Investing.com
Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus - TipRanks
Bluejay responds to investor on possible therapeutic acquisition while prioritizing Symphony platform execution - TradingView
Bluejay Diagnostics (BJDX) reviews NorthStrive proposal for cough therapy acquisition - Stock Titan
Buyout Rumor: What is Bluejay Diagnostics Incs book value per shareTrade Exit Summary & Real-Time Volume Analysis - baoquankhu1.vn
Bluejay Diagnostics, Inc. announced that it expects to receive $0.125 million in funding - marketscreener.com
Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program - TipRanks
Bluejay Diagnostics: SYMON-I IL-6 Findings Accepted for SAEM 2026 Presentation - TradingView
Bluejay Diagnostics (NASDAQ: BJDX) highlights SYMON-I IL-6 sepsis data at 2026 SAEM - Stock Titan
Bluejay Diagnostics to Present Findings on IL-6 as a Biomarker for Sepsis at 2026 SAEM Annual Meeting - Quiver Quantitative
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting - The Manila Times
Study explores link between ER inflammation marker and organ damage in sepsis - Stock Titan
Northstrive Fund II has sent a letter to the Board of Directors of Bluejay Diagnostics Inc, recommending that they carefully evaluate a potential acquisition opportunity. - Bitget
Bluejay Diagnostics Inc Stock (BJDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):